<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51910">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01852630</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS- SBP-001</org_study_id>
    <nct_id>NCT01852630</nct_id>
  </id_info>
  <brief_title>Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure</brief_title>
  <official_title>A Randomized, Comparative Open Label Study of Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <authority>India: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. All consecutive patients with Cirrhosis and ascites admitted to ILBS (Institute of
           Liver &amp; Biliary Sciences) will be evaluated for the presence of SBP (Spontaneous
           Bacterial Peritonitis) by ascitic fluid examination at admission.

        2. SBP (Spontaneous Bacterial Peritonitis) will be diagnosed in the presence of absolute
           neutrophil count (ANC &gt;250/mm3) with/without positive ascitic fluid culture and
           Patients with SBP (Spontaneous Bacterial Peritonitis) included in the study will be
           randomized to receive cefepime or imipenem.

        3. However, other SBP (Spontaneous Bacterial Peritonitis) patients not included for
           randomization will be given empirical therapy with 3rd generation cephalosporin
           (ceftriaxone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline evaluation:

      Baseline clinical, laboratory and disease severity parameters will be evaluated for each
      study patient.

        1. Etiology of cirrhosis.

        2. Severity of liver disease. CTP (Child-Turcotte-Pugh) score MELD (Model for End-stage
           Liver Disease) score MELD (Model for End-stage Liver Disease)-Na score IMSAA score

        3. Decompensations/complications of CLD (Chronic Liver Disease) UGI bleed, Hepatic
           encephalopathy, AKI (Acute Kidney Injury) etc.

        4. Laboratory investigations:

      Serum electrolytes Liver function tests Kidney function tests Pro calcitonin USG/CT abdomen
      Complete blood counts Coagulation parameters Ascitic fluid analysis- TLC, DLC, Protein,
      sugar, culture, SAAG. Chest X ray PA view HBsAg and Anti-HCV and other etiological workup as
      available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary outcome of the study is the Response to treatment in each intervention group. Response is defined as 25% reduction in ANC (Absolute Neutrophil Count) from baseline.</measure>
    <time_frame>2 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>15 days,1 month and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Spontaneous Bacterial Peritonitis (SBP).</condition>
  <arm_group>
    <arm_group_label>cefepime + Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cefepime 1g iv 8 hourly + Albumin will be given for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipenem + Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime + Albumin</intervention_name>
    <description>cefepime + Albumin will be given for 2 days</description>
    <arm_group_label>Imipenem + Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem + Albumin</intervention_name>
    <description>Imipenem + Albumin will be given for 2 days.</description>
    <arm_group_label>cefepime + Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Cirrhotic Patients with SBP (Spontaneous Bacterial Peritonitis) having any of the
        following risk factors would be considered as  'Difficult to Treat SBP'  and would be
        included -

          1. Nosocomial SBP: occurence of SBP (Spontaneous Bacterial Peritonitis) after 48 hours
             of hospital admission, or

          2. Prior ascitic fluid infection with 3rd generation cephalosporin resistant organism,
             or

          3. No response to treatment with 3rd generation cephalosporins after 48 hours.

        Exclusion Criteria:

          1. Age less than 18 years.

          2. Cirrhotics with SBP (Spontaneous Bacterial Peritonitis) managed as outpatients.

          3. Post liver transplant, HIV patients.

          4. Patients on systemic chemotherapy, immunosuppressant drugs.

          5. Growth of bacteria resistant to intervention drugs in ascitic fluid culture.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Ankur Jindal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences (ILBS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Ankur Jindal, MD</last_name>
    <phone>+91-9582670984</phone>
    <email>ankur.jindal3@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences (ILBS)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ankur Jindal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 14, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
